Yu Jiang

Dr. Yu Jiang


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2020 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
PDPeixin Du
Peixin Du
HZHao Zeng
Hao Zeng
YXYinan Xiao
Yinan Xiao
YZYunuo Zhao
Yunuo Zhao
BZBo Zheng
Bo Zheng
Xuelei MaXuelei Ma
Xuelei Ma
Chronic stress could induce cancer metastasis by constant activation of the sympathetic nervous system, while cellular mechanism remains obscure. The aim of this research is to explore the metastasis associated negative effect of chronic stress. The analysis of transcriptome sequencing implied that activation of STAT3 signaling pathway by downregulated miR-337-3p might be a potential mechanism to induce epithelial to mesenchymal transition (EMT) of cancer cell and promote metastasis under chronic stress. We also verified this biological process in further experiments. Downregulation of miR-337-3p could downregulate E-cadherin expression and upregulate vimentin expression in vitro and in vivo. STAT3, related signal pathways of which are involved in metastasis regulation, was directly targeted by miR-337-3p. In conclusion, the above results denoted that activation of miR-337-3p/STAT3 axis might be a potential pathway for the increasing metastasis of breast cancer under chronic stress.

1 November 2019 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
Keyi YangKeyi Yang
Keyi Yang
ZZZhi Zeng
Zhi Zeng
HPHu Peng
Hu Peng
YJYu Jiang
Yu Jiang
Purpose: Artificial intelligence (AI) plays a substantial role in many domains, including medical fields. However, we still lack evidence to support whether or not cancer patients will accept the clinical use of AI. This research aims to assess the attitudes of Chinese cancer patients toward the clinical use of artificial intelligence in medicine (AIM), and to analyze the possible influencing factors. Patients and methods: A questionnaire was delivered to 527 participants. Targeted people were Chinese cancer patients who were informed of their cancer diagnosis. Results: The effective response rate was 76.3% (402/527). Most cancer patients trusted AIMs in both stages of diagnosis and treatment, and participants who had heard of AIMs were more likely to trust them in the diagnosis phase. When an AIM’s diagnosis diverged from a human doctor’ s, ethnic minorities, and those who had received traditional Chinese medicine (TCM), had never received chemotherapy, were more likely to choose “AIM”, and when an AIM’s therapeutic advice diverged from a human doctor’s, male participants, and those who had received TCM or surgery, were more likely to choose “AIM”. Conclusion: Most Chinese cancer patients believed in the AIM to some extent. Nevertheless, most still thought that oncology physicians were more trustworthy when their opinions diverged. Participants’ gender, race, treatment received, and AIM related knowledge might influence their attitudes toward the AIM. Most participants thought AIM would assist oncology physicians in the future, while little really believed that oncology physicians would completely be replaced.

19 May 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
BWBin Wang
Bin Wang
JLJie Liu
Jie Liu
YHYin Han
Yin Han
YDYaotiao Deng
Yaotiao Deng
JLJinze Li
Jinze Li
YJYu Jiang
Yu Jiang
Background: Tertiary lymphoid structures (TLSs) have been proven to be predictive biomarkers of favorable clinical outcomes and response to immunotherapies in several solid malignancies. Nevertheless, the effect of TLSs in patients with breast cancer (BC) remains controversial. The objective of the current study is to investigate the clinicopathological and prognostic significance of TLSs in BC. Given the unique difficulties for detecting and quantifying TLSs, a TLS-associated gene signature based on The Cancer Genome Atlas (TCGA) BC cohort was used to validate and supplement our results.Methods: Electronic platforms (PubMed, Web of Science, EMBASE, the Cochrane Library, CNKI, and Wanfang) were searched systematically to identify relevant studies as of January 11, 2022. We calculated combined odds ratios (ORs) with 95% confidence intervals (CIs) to determine the relationship between clinicopathological parameters and TLSs. The pooled hazard ratios (HRs) and 95% CIs were also calculated to evaluate the prognostic significance of TLSs. The TLS signature based on the TCGA BC cohort was applied to validate and supplement our results.Results: Fifteen studies with 3,898 patients were eligible for enrollment in our study. The combined analysis indicated that the presence of TLSs was related to improved disease-free survival (DFS) (HR = 0.61, 95% CI: 0.41–0.90, p < 0.05) and overall survival (OS) (HR = 1.66, 95% CI: 1.26–2.20, p < 0.001). Additionally, the presence of TLSs was positively correlated with early tumor TNM stage and high tumor-infiltrating lymphocytes. TLS presence was positively related to human epidermal growth factor receptor 2 (HER-2) and Ki-67 but inversely correlated with the status of estrogen and progesterone receptor. Simultaneously, our study found that tumor immune microenvironment was more favorable in the high-TLS signature group than in the low-TLS signature group. Consistently, BC patients in the high-TLS signature group exhibited better survival outcomes compared to those in the low-TLS signature group, suggesting that TLSs might be favorable prognostic biomarkers.Conclusions: TLS presence provides new insight into the clinicopathological features and prognosis of patients with BC, whereas the factors discussed limited the evidence quality of this study. We look forward to consistent methods to define and characterize TLSs, and more high-quality prospective clinical trials designed to validate the value of TLSs alone or in combination with other markers.

15 December 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
YSYuan-kai Shi
Yuan-kai Shi
QCQiqing Cai
Qiqing Cai
YJYu Jiang
Yu Jiang
GHGang Huang
Gang Huang
MBMinghong Bi
Minghong Bi
CGChao Gao
Chao Gao
Purpose: Patients with alveolar soft part sarcoma (ASPS) are rare and have few treatment options. We assessed the activity of geptanolimab (GB226), a fully humanized PD-1 antibody, for patients with unresectable, recurrent or metastatic ASPS. Patients and methods: We did this multicentre, single-arm, phase 2 study (Gxplore-005,NCT03623581) in patients aged 18-75 years who had unresectable, recurrent or metastatic ASPS at 11 sites in China. Patients received intravenous geptanolimab (3 mg/kg) every 2 weeks until disease progression or unacceptable toxicity. The primary endpoint was objective response rate assessed by independent review committee (IRC) per RECIST 1.1 in the full analysis set population. Results: Between September 6, 2018 and March 6, 2019, we enrolled and treated 37 patients with 23 (62.2%) having received prior systemic treatment. 14 (37.8%, 95% confidence interval [CI] 22.5-55.2) of 37 patients had an objective response assessed by IRC with a 6-month duration of response rate of 91.7%. Median progression-free survival was 6.9 months (95% CI 5.0-not reached) and disease control was achieved in 32 (86.5%, 95% CI 71.2-95.5) patients. Three of 37 patients reported grade 3 treatment-related adverse events (TRAEs), including anaemia, hypophysitis and proteinuria (one each [2.7%]). No grade 4 TRAEs were observed. Two (5.4%) patients discontinued treatment due to TRAE (one with hypophysitis and one with Mobitz type I atrioventricular block). The baseline percentage of CD4+ T cells was adversely associated with patient response (P=0.031). Conclusions: Geptanolimab has clinically meaningful activity and a manageable safety profile in unresectable, recurrent or metastatic ASPS.

13 June 2025 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
YWYusha Wang
Yusha Wang
JHJing Huang
Jing Huang
HTHuan Tong
Huan Tong
YJYuting Jiang
Yuting Jiang
YJYu Jiang
Yu Jiang
Xuelei MaXuelei Ma
Xuelei Ma

22 February 2022 in Cancer Medicine
Verified
Journal Article
Open access
RZRen‐Shu Zhang
Ren‐Shu Zhang
JLJie Liu
Jie Liu
YDYao‐Tiao Deng
Yao‐Tiao Deng
XWXin Wu
Xin Wu
YJYu Jiang
Yu Jiang
Background: The ALTER0203 clinical trial showed that anlotinib, a multitargeted tyrosine kinase inhibitor, had antitumor effects on advanced soft tissue sarcoma (STS) after the failure of standard chemotherapy. We aimed to evaluate the real‐world efficacy and explore prognostic factors and treatment patterns of anlotinib in patients with advanced STS.Methods: We retrospectively analyzed the data of patients with unresectable locally advanced or metastatic STS who received at least one dose of anlotinib from June 2018 to March 2021. The survival data were analyzed using the Kaplan–Meier method and compared using the log‐rank test. The Cox proportional hazards model was performed for multivariate analysis.Results: A total of 209 patients were included. The median age was 48 (range 11–85) years. The median follow‐up, progression‐free survival, and overall survival were 18.7 months, 6.1 months [95% confidence interval (CI): 4.9–7.2], and 16.4 months (95% CI: 13.6–19.1), respectively. The objective response rate was 13.4%. Nutritional status, Eastern Cooperative Oncology Group (ECOG) performance status, and anlotinib treatment patterns (combination therapy or switch maintenance therapy vs. monotherapy) were significantly associated with progression‐free survival. Besides, pathological grade, nutritional status, ECOG performance status, and anlotinib treatment patterns were predictive of overall survival. Due to anlotinib‐related toxicity, 31 (14.8%) patients, and 25 (12.0%) patients experienced dose reduction and treatment discontinuation, respectively.Conclusion: These findings confirmed the efficacy of anlotinib in patients with advanced STS in a real‐world setting. The patterns of anlotinib treatment deserve further exploration.